The existing drug treatments for managing diabetes such as insulin secretagogues (sulfonylureas), insulin sensitizers (biguanides and thiazolidinediones), alpha-glucosidase inhibitors (miglitol, acarbose), and glucagon-like peptide-1 (GLP-1) agonists possess certain constraints, underscoring the necessity for safer and more potent antidiabetic medications. This evidence concerns the gene GCG and diabetes mellitus.